Sustainable and affordable access to novel drug therapies is increasingly at stake, while simultaneously, substantial drug quantities are being wasted after remaining unused by patients. Given the economic and environmental impacts of this waste, new strategies targeting waste of expensive therapies, such as oral anticancer drugs, are required. My PhD research contributed to the design and evaluation of two waste-minimising strategies, aiming to 1) reduce waste by individualising dispensed quantities, and 2) redispense (i.e., reuse) unused drugs to other patients after quality assurance. Feasibility of individualising dispensed quantities was demonstrated among 50 patients initiating oral anticancer drugs. It reduced wasted tablets/capsules quantities by one-third and was highly accepted by patients and pharmacy employees, yet left room for further waste-minimisation. A redispensing strategy for unused oral anticancer drugs was created collaboratively with patients with cancer and tested in a multicentre intervention study including > 1,000 patients. Wasted packages were reduced by two-third, equalling mean annual cost-savings up to €1,348 (95% 1,039 – 1,697) per patient and mean annual environmental benefits up to 1 kg CO2per patient.In conclusion, we showed that reduce and reuse strategies contribute to sustainable use of novel drug therapies by improving their affordability and environmental impact.